Next Article in Journal
Plants Used for the Traditional Management of Cancer in the Eastern Cape Province of South Africa: A Review of Ethnobotanical Surveys, Ethnopharmacological Studies and Active Phytochemicals
Next Article in Special Issue
New Pharmacological Strategies against Pancreatic Adenocarcinoma: The Multifunctional Thiosemicarbazone FA4
Previous Article in Journal
Pharmacoinformatics and UPLC-QTOF/ESI-MS-Based Phytochemical Screening of Combretum indicum against Oxidative Stress and Alloxan-Induced Diabetes in Long–Evans Rats
 
 
Article
Peer-Review Record

Isobavachalcone as an Active Membrane Perturbing Agent and Inhibitor of ABCB1 Multidrug Transporter

Molecules 2021, 26(15), 4637; https://doi.org/10.3390/molecules26154637
by Anna Palko-Łabuz, Maria Błaszczyk, Kamila Środa-Pomianek * and Olga Wesołowska
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Molecules 2021, 26(15), 4637; https://doi.org/10.3390/molecules26154637
Submission received: 7 July 2021 / Revised: 26 July 2021 / Accepted: 29 July 2021 / Published: 30 July 2021
(This article belongs to the Special Issue Bioactive Molecules as Multidrug Resistance Modulators)

Round 1

Reviewer 1 Report

The manuscript presents studies of great interest to the pharmaceutical and medical field regarding ABCB1 multidrug transporter inhibitors. 

  1. What were the criteria for choosing the membrane models (DMPC and DPPC) on which the studies were performed?
  2. For subsection 2.5, a comparison of the data obtained for IBC with those for a known inhibitor would provide additional data. 

Author Response

separate file uploaded

Author Response File: Author Response.pdf

Reviewer 2 Report

The manuscript from Palko-Labuz et al investigated the cytotoxic, multidrug resistance, and ABCB1 transporter modulation effects of the active substance Isobavachalcone from medical plant, using two cancer cell lines. It is revealed that IBC might act as an ABCB1 transporter modulator and it is nicely shown by the authors through differential scanning calorimetry that IBC is a potent lipid bilayer modifier. The data are presented with sufficient analysis and the conclusions are reasonably supported by the observations. Overall, the text is logical and well written.

It is nice to see the difference that IBC killed more MDKC cells than MDKC-MDR1 cells which have overexpressed ABCB1 transporters. And the authors show that Ver the ABCB1 inhibitor make MDKC-MDR1 cells more vulnerable to IBC. It is surprising though that low concentrations of IBC not only did not kill MDKC-MDR1 cells but also significantly stimulated the growth of the MDKC-MDR1, could the authors comment on the stimulation effect in the discussion?

Some references in the Results section are missing, for example:

    Line 100, add reference for verapamil

    Line 114, add reference for Dox

    Line147, add reference for the Rho123 assay

Typos I identified in the text:

     Line 92, “ICB” should be “IBC”

     Line 117-118, “(Figure 2B and 2B, respectively)”, please fix

     Line 179, “form” seems should be “from”

Author Response

separate file uploaded

Author Response File: Author Response.pdf

Back to TopTop